Aridis Pharmaceuticals Inc. (ARDS) Shares: Cheap or Risky?


Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) saw a downside of -28.21% to close Tuesday at $0.84 after subtracting -$0.33 on the day. The 5-day average trading volume is 2,813,620 shares of the company’s common stock. It has gained $1.4500 in the past week and touched a new high 3 times within the past 5 days. An average of 833,245 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 391,556.

ARDS’s 1-month performance is -18.45% or -$0.1900 on its low of $0.5700 reached on 01/24/23. The company’s shares have touched a 52-week low of $0.68 and high of $2.94, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, ARDS has lost -28.81% or -$0.3400 and has reached a new high 1 time. However, the current price is down -71.43% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

ARDS stock has a beta of 1.21. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.53.

Aridis Pharmaceuticals Inc.’s quick ratio for the period ended September 29 was 0.20, with the current ratio over the same period at 0.20. The firm’s gross profit as reported stood at $44.25 million against revenue of $1.53 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -192.96% to -$8.24 million, while revenue of -$7.98 million was 3.16% off the previous quarter. Analysts expected ARDS to announce -$0.17 per share in earnings in its latest quarter, but it posted -$0.47, representing a -176.50% surprise. EBITDA for the quarter stood at more than -$7.29 million. ARDS stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 47.94 million, with total debt at $14.08 million. Shareholders hold equity totaling $20.8 million.

Let’s look briefly at Aridis Pharmaceuticals Inc. (ARDS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 24.94% to suggest the stock is trending oversold, with historical volatility in this time period at 166.23%.

The stock’s 5-day moving average is $1.1440, reflecting a -35.38% or -$0.4600 change from its current price. ARDS is currently trading -15.15% above its 20-day SMA, -45.81% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +4.33% and SMA200 by-45.45%.

Stochastic %K and %D was 26.20% and 34.52% and the average true range (ATR) pointed at 0.2655. The RSI (14) points at 33.57%, while the 14-day stochastic is at 24.75% with the period’s ATR at 0.2277. The stock’s 9-day MACD Oscillator is pointing at -0.1481 and -0.2083 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Aridis Pharmaceuticals Inc. (NASDAQ: ARDS), ROTH Capital launched coverage with a Buy rating. Analysts offering their rating for ARDS stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ARDS as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.

What is ARDS’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $2.00 and a high of $19.00, with their median price target at $10.50. Looking at these predictions, the average price target given by analysts is for Aridis Pharmaceuticals Inc. (ARDS) stock is $10.50.


Please enter your comment!
Please enter your name here